获得性免疫缺陷综合症(AIDS)是存在于其它类型疾病的最终结局,如与AIDS 相关的综合疵或淋巴腺病综合症以及无症状免疫缺陷带毒者。有人己开始对供血者进行HTLV-Ⅱ/LAV 的抗体筛选工作。但这种试验仅能了解有无病毒接触史,而不能检测病毒的存在或者预测疾病的发生。所以需要另外的试验以提供机体免疫系统对HTLV-Ⅱ的应答的量的估价。其它可用于定量的标记物之一是β_2-徽球蛋白(β_2 m),它是一种人白细胞抗原的轻链小分子多肽,是T 和B 细胞受体的一部份。在淋巴增殖性疾 Acquired immunodeficiency syndrome (AIDS) is the ultimate outcome of other types of diseases, such as AIDS-related complex defects or lymphatic syndrome and asymptomatic immunodeficiency. Some people have begun to HTLV-Ⅱ / LAV donor antibody screening work. But this test can only know whether there is a history of virus exposure, but can not detect the presence of the virus or predict the occurrence of the disease. Additional testing is therefore required to provide an estimate of the amount of HTLV-II response in the body’s immune system. One of the other markers that can be used for quantification is the beta 2-emu protein (β_2 m), a light chain small molecule polypeptide of human leukocyte antigen that is part of the T and B cell receptors. In lymphoproliferative disorders